Shares of vaccine makers closed lower Thursday amid reports that President-elect Donald Trump was set to nominate vaccine ...

Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and ...

Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, ...

Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00.

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled. A ...

Most people don't enjoy getting shots for treatments or vaccines. So, researchers are working to create more medicines, such as those made from messenger RNA (mRNA), that can be sprayed and inhaled.

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

Curevac N.V. ( (CVAC) ) has released its Q3 earnings. Here is a breakdown of the information Curevac N.V. presented to its investors. CureVac ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

CureVac NV (CVAC) reports robust revenue growth and strategic advancements in oncology, despite ongoing litigation challenges.

Belgium has solidified its position as a European leader in pharmaceutical research and development with a daily investment ...